127 results on '"van Beek, Johan"'
Search Results
2. Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study.
3. A smartphone sensor-based digital outcome assessment of multiple sclerosis
4. The Patient‐Determined Disease Steps scale is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis.
5. Patient‐determined disease steps is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis
6. In a Digital Version of the 9-Hole Peg Test, Intra-Task Speed, Accounting for Variance in Distance Traveled, May be a Better Measure of MS-Related Upper-Limb Disability Than Completion Time. (P3-3.006)
7. Preliminary validity of the Draw a Shape Test for upper extremity assessment in multiple sclerosis
8. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial
9. Inflammation in parkinson’s disease : Causative or epiphenomenal?
10. The Role of Complement in EAE
11. Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS
12. sj-docx-1-msj-10.1177_13524585221097561 – Supplemental material for Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS
13. Preliminary validity of the Draw a Shape Test for upper extremity assessment in multiple sclerosis.
14. Digital health: Smartphone-based monitoring of multiple sclerosis using Floodlight.
15. Oostenrijk tegen NAVO maar voor Europees leger
16. A smartphone sensor-based digital outcome assessment of multiple sclerosis
17. sj-docx-1-msj-10.1177_13524585211028561 – Supplemental material for A smartphone sensor-based digital outcome assessment of multiple sclerosis
18. sj-pdf-1-msj-10.1177_13524585211028561 – Supplemental material for A smartphone sensor-based digital outcome assessment of multiple sclerosis
19. Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance
20. Smartphone- and Smartwatch-Based Remote Characterisation of Ambulation in Multiple Sclerosis During the Two-Minute Walk Test
21. Nonhematopoietic Erythropoietin Derivatives Prevent Motoneuron Degeneration In Vitro and In Vivo
22. Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen–glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures
23. Roles of the complement system in human neurodegenerative disorders: Pro-inflammatory and tissue remodeling activities
24. Effect of Ocrelizumab on Thalamic Atrophy in Patients with Relapsing and Primary Progressive Multiple Sclerosis (1286)
25. Nest building performance following MPTP toxicity in mice
26. Reduced Functional Deficits, Neuroinflammation, and Secondary Tissue Damage after Treatment of Stroke by Nonerythropoietic Erythropoietin Derivatives
27. Evidence of Oatp and Mdr1 in cryopreserved rat hepatocytes
28. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity
29. Activation of Complement in the Central Nervous System: Roles in Neurodegeneration and Neuroprotection
30. Semiconductor assembly council promotes use of quality tools
31. Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study
32. PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE
33. Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis (P5.407)
34. OPTIMISE - A Web-Based Solution for Recording and Analyzing Longitudinal Multiple Sclerosis Data (P2.116)
35. ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis
36. Performances cognitives variables associées aux codes fixe ou dynamique au sein du test de vitesse de traitement cognitif (CPS) de l’application KonectomTM sur smartphone
37. An Exploratory Analysis of Magnetic Resonance Imaging Outcomes in the DreaMS Trial: A Double-Blind, Placebo-Controlled, Phase 2, 26-Week Trial of a Selective Sphingosine 1-Phosphate Receptor Agonist ONO-4641 in Patients with Relapsing–Remitting Multiple Sclerosis (S31.005)
38. Molecular basis for detection of invading pathogens in the brain
39. Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor
40. Reduced Functional Deficits, Neuroinflammation, and Secondary Tissue Damage after Treatment of Stroke by Nonerythropoietic Erythropoietin Derivatives
41. Decay-Accelerating Factor (CD55) Is Expressed by Neurons in Response to Chronic but Not Acute Autoimmune Central Nervous System Inflammation Associated with Complement Activation
42. P3-202 Neuroprotective properties of memantine in different models of excitotoxicity
43. Disruption of Neurogenesis on Gestational Day 17 in the Rat Causes Behavioral Changes Relevant to Positive and Negative Schizophrenia Symptoms and Alters Amphetamine-Induced Dopamine Release in Nucleus Accumbens
44. Innate immunity and brain inflammation: the key role of complement
45. Inflammation in parkinson's disease.
46. The Role of Complement in EAE.
47. Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death
48. Glial responses, clusterin, and complement in permanent focal cerebral ischemia in the mouse
49. Expression of Receptors for Complement Anaphylatoxins C3a and C5a Following Permanent Focal Cerebral Ischemia in the Mouse
50. Progressive Degeneration of Human Mesencephalic Neuron-Derived Cells Triggered by Dopamine-Dependent Oxidative Stress Is Dependent on the Mixed-Lineage Kinase Pathway.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.